Danazol therapy combined with intermittent application of chemotherapy induces lasting remission in myeloproliferative disorder (MPD): an alternative for the elderly with advanced MPD

References

• Hoffman R, Ravandi-Kashani F. Idiopathic myelofibrosis. In: , Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P editors. Blood Philadelphia, PA: Elsevier Churchill Livingstone, Inc.; 2005. 1255–76.
   Google Scholar
• Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000;95:2226–33.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Tefferi A. Splenic irradiation in myelofibrosis with myeloid metaplasia: a review. Blood Rev 1999;13:163–70.
   PubMed Web of Science ®Google Scholar
• Matsukawa Y, Ikeda E, Suguro H, Iizuka Y, Nishinarita S, Hayama T, et al.. Successful high-dose methylprednisolone therapy in a patient with primary myelofibrosis. Rinsho Ketsueki 1990;31:1674–9.
   PubMedGoogle Scholar
• Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005;74:117–20.
   PubMed Web of Science ®Google Scholar
• Chee L, Kalnins R, Turner P. Low dose melphalan in the treatment of myelofibrosis: a single center experience. Leuk Lymphoma 2006;47:1409–12.
   PubMed Web of Science ®Google Scholar
• Gilbert HS. Long term treatment of myeloproliferative disease with interferon-2b: feasibility and efficacy. Cancer 1998;83:1205–13.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 2004;79:883–9.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Bjerrum OW, Jensen BA, Clausen NT, Hansen PB, Birgens H, et al.. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am J Hematol 2003;74:238–42.
   PubMed Web of Science ®Google Scholar
• Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, et al.. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101:1692–7.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, et al.. Allogenic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003;102:12.
   Web of Science ®Google Scholar
• Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S, et al.. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma 2006;47:441–50.
   PubMed Web of Science ®Google Scholar
• Kreft A, Weiss M, Wiese B, Choritz H, Buhr T, Busche G, et al.. Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. A retrospective study identifying subgroups of different prognoses by using the RECPAM method. Ann Hematol 2003;82:605–11.
   PubMed Web of Science ®Google Scholar
• Kolodny L, Horstman LL, Sevin BU, Brown H, Ahn YS. Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases. Am J Haematol 1996;51:112–6.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000;85:595–9.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005;129:771–5.
   PubMed Web of Science ®Google Scholar
• Levy V, Bourgarit A, Delmer A, Legrand O, Baudard M, Rio B, et al.. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol 1996;53:239–41.
   PubMed Web of Science ®Google Scholar
• Besa EC, Nowell PC, Geller NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982;49:308–13.
   PubMed Web of Science ®Google Scholar
• Hast R, Engstedt L, Jameson S, Killander A, Lundth B, Reizenstein P, et al.. Oxymetolone treatment in myelofibrosis. Blut 1978;37:19–26.
   PubMedGoogle Scholar
• Madanes AE, Farber M. Danazol. Ann Intern Med 1982;96:625–30.
   PubMed Web of Science ®Google Scholar
• Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 1983;308:1396–99.
   PubMed Web of Science ®Google Scholar
• Ahn YS. Efficacy of Danazol in hematologic disorders. Acta Haematol 1990;84:122–9.
   PubMed Web of Science ®Google Scholar
• Randi ML, Luzzatto G, Fabris F. Danazol in refractory pruritus of myeloproliferative disorders. Am J Hematol 1997;54:172–3.
   PubMed Web of Science ®Google Scholar
• Kuramoto K, Follman D, Heinatti P, Sellers S, Laukkanen MO, Seggewiss R, et al.. The impact of low-dose busulfan on clonal dynamics in nonhuman primates. Blood 2004;104:1273–80.
   PubMed Web of Science ®Google Scholar
• Charbord P, Neel H, Caillou B, Kahn E, Parmentier C. Effect of alkylating agents on hematopoiesis in myelofibrosis. 4 case report. Nouv Re Fr Hematol 1984;26:361–9.
   PubMedGoogle Scholar
• Chang JC, Gross HM. Remission of chronic idiopathic myelofibrosis to busulfan treatment. Am J Med Sci 1988;295:472–6.
   PubMed Web of Science ®Google Scholar
• Uemura Y, Iwahara Y, Kataoka R, Muneishi H, Miyoshi L. Successful treatment of primary myelofibrosis by busulfan pulse therapy: report of a case. Rinsho Ketsueki 1990;31:1553–6.
   PubMedGoogle Scholar
• Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues in cancer treatment. Lancet Oncol 2002;3:415–24.
   PubMed Web of Science ®Google Scholar
• Whitehead S, Geary CG. Low dose cytosine arabinoside used to induce remission in acute myelofibrosis. Br J Haematol 1984;58:375–6.
   PubMed Web of Science ®Google Scholar
• Niki T, Kawanura Y. Hematological remission of primary myelofibrosis with antiphospholipid antibody following treatment with azathioprine. Rinsho Ketsueki 1995;36:141–6.
   PubMedGoogle Scholar
• Camba L, Aldrighetti L, Ciceri F, Bernardi M, Marktel S, Angeli E, et al.. Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis. Br J Haematol 2001;114:638–40.
   PubMed Web of Science ®Google Scholar
• Takabayashi M, Sakai R, Kanamori H, Ishigatsubo Y. Successful treatment with intermediate dose of cytosine arabinoside for myelodyspalstic syndrome with acute myelofibrosis. Leuk Lymphoma 2003;44:891–2.
   PubMed Web of Science ®Google Scholar